GHP Q2 2018

GHP / Q2 2018 5 NEWS , GS1 US ® has ap- pointed the follow- ing executives to its Board of Governors: Dawn Block, senior vice president, digital at Target; Nick Loporcaro, president of McKesson U.S. Pharmaceuti- cal and Specialty Health; Sunita Mani, general manager at Google Store; and Meredith G. Stevens, vice president, strategy and de- ployment, Johnson & Johnson Supply Chain. All executives will help guide the GS1 US strategy to drive adoption and use of GS1 Stand- ards across multiple industries to support innovation, improved supply chain efficiencies, e-com- merce operations, regulatory requirements, and the demands of today’s empowered consum- er, including more accurate and complete product information. “Businesses today need to be able to act with agility and speed to keep pace with consumers,” said Bob Carpenter, president and CEO of GS1 US. “These leaders recognise the value of GS1 Standards to establish unique identification of products and associated metadata, plus interoperability across a growing ecosystem of technologies and partners. I look forward to their collaboration as we continue to shape the future of business.” Ms. Block oversees digital strate- gy and teams including site mer- chandising, digital products and solutions, user experience (UX) and design as senior vice pres- ident of digital at Target. In her previous role, Ms. Block oversaw Target’s first fully-integrated enter- prise merchandising team, con- sisting of beauty and household essentials. Prior to joining Target in 2013, Ms. Block spent a dec- ade at Hayneedle, including near- ly three years as vice president of merchandising with oversight of product development, sourcing, new business development, pric- ing and inventory planning. As president of McKesson U.S. Pharmaceutical and Specialty Health, Mr. Loporcaro oversees Bernhardt Zeiher, M.D. joins com- pany’s executive leadership team. Astellas is pleased to announce that Bernhardt G. Zeiher, M.D., F.C.C.P., F.A.C.P., (“Bernie”), was promoted to Chief Med- ical Officer (CMO), effective April 1, 2018. Zeiher will con- tinue serving as president of Development, while now also overseeing all other functions of Astellas’ Medical and Devel- opment (M&D) organisation, including Clinical and Research Quality Assurance, Medical Af- fairs, Pharmacovigilance, Plan- ning & Administration, and Reg- ulatory Affairs. Reporting directly to Astellas president and CEO, Kenji Yas- ukawa, Ph.D., Zeiher will join the company’s top executive leadership team. He will con- tinue to lead the organisation from Northbrook, Ill., Astellas’ headquarters for M&D and its Americas operations. In his new role, Zeiher will focus on further integrating and en- hancing Astellas’ delivery of its global innovative pipeline and driving support for the appropri- ate use of its products. “I am honoured to lead the As- tellas M&D organisation during this critical time,” said Zeiher. “As we embark upon a new Corporate Strategic Plan, it is my goal to continue and further implement the corporate vision of turning innovative science into value for patients.” all operations, including the dis- tribution of pharmaceuticals, vaccines, and other health- care-related products, as well as technology and value-added ser- vices to customers. Previously, he was president of McKesson Specialty Health and president of McKesson Canada, where he led the integration of Drug Trad- ing and Medicine Shoppe, po- sitioning McKesson Canada as the largest banner of independ- ent pharmacists across Canada. Prior to joining McKesson, Mr. Loporcaro was managing part- ner with Ascend LLC, a business development and management consultancy which he founded. He also worked in progressively responsible management and ex- ecutive roles in a variety of sec- tors, notably telecommunications and manufacturing. Ms. Mani leads product engi- neering and business operations as general manager of Google Store, where she has end-to- end responsibility for this online shop where you can buy Made by Google hardware, Nest devices and Made for Google accesso- ries. Prior to this role, she was director of, and she ad- ditionally spent 10 years at eBay, where she was vice president of product and engineering for sell- ing, trust, payments, and ship- ping. Ms. Mani recently delivered the keynote speech for Google’s “She’s So STEM” program to en- courage young women to explore a career in technology. At Johnson & Johnson, Ms. Ste- vens is responsible for leading end-to-end strategy and trans- formation in the areas of supply chain innovation, digitalisation, value chain management, plan- ning and performance. She held several key leadership positions prior to joining J&J, including chief supply chain officer at Newell Rubbermaid, vice president of global operations at Tyco Interna- tional, and roles at General Elec- tric, Bertelsmann, Inc. and Knoll Inc. Ms. Stevens is also an active member of the Smithsonian Sci- ence Education Center and the Rensselaer Polytechnic Institute Supply Chain Advisory Boards. Astellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer Zeiher started his career at As- tellas in 2010 as vice president and Therapeutic Area leader for Inflammation, Immunology and Infectious Diseases. He was pro- moted to senior vice president and Therapeutic Area Head for Immu- nology, Infectious Diseases and Transplant in 2012. Zeiher was lat- er named executive vice president and Therapeutic Area Head when his organisation was expanded to include the company’s CNS and Pain programs. Most recently, Zei- her was promoted to president of Development in 2015. Prior to join- ing Astellas, Zeiher served as the vice president of the Inflammation/ Immunology therapeutic area at Pfizer. He earned his Doctor of Medicine at the Case Western Reserve Uni- versity School of Medicine, and completed an internal medicine residency at University Hospitals of Cleveland as well as a fellow- ship in Pulmonary and Critical Care Medicine at University of Iowa Hospitals and Clinics. Zeiher is a Fellow in the American Col- lege of Physicians and the Amer- ican College of Chest Physicians. He has worked in the pharmaceu- tical industry since 1998.